Varenicline
DrugOther names: Chantix
NCT Number: NCT01406223
The purpose of this study is to look at brain function in order to understand how different treatments work to help people quit smoking. In this study, the investigators will look at the effects of nicotine patches, Chantix alone or Chantix paired with Zyban.
Looking for future studies?
Notify Me18 year–50 year
All sexes
Interventional
Phase 3
Duke Center for Nicotine and Smoking Cessation Research, Durham, North Carolina, United States
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Potential subjects must agree to avoid the following during their participation in this study:
Exclusion criteria
Other names: Chantix
Other names: Zyban
Other names: Nicoderm
Time frame: change from baseline in whole brain blood-oxygen-level dependent (BOLD) contrast sensitive functional magnetic resonance imaging (fMRI) images collected during a cue-reactivity task following 2 weeks of pre-quit treatment
Mean blood-oxygen-level dependent (BOLD) contrast sensitive functional magnetic resonance imaging (fMRI) cue-reactivity signal following 2 week pre-quit treatment, controlling for baseline cue-reactivity.
Time frame: Up to 11 weeks post quit day.
Days to first cigarette (i.e. lapse) will be measured via self-report.
Duke University
Other
Acronym: ConNicBrain
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03083353
Behavior, Chemically-Induced Disorders
Austin, Texas, United States
View Trial DetailsNCT03904186
Acquired Immunodeficiency Syndrome, Anhedonia
Boston, Massachusetts, United States
View Trial DetailsNCT05095779
Behavior, Chemically-Induced Disorders
Oklahoma City, Oklahoma, United States
View Trial DetailsNCT04159571
Addiction, Addiction Nicotine
Winston-Salem, North Carolina, United States
View Trial Details